<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Aggressive B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (BCL) comprises a <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> group of <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>, including diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>), Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, and mantle cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>, with its 3 subtypes, is the most common type of <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Advances in chemoimmunotherapy have substantially improved disease control </plain></SENT>
<SENT sid="3" pm="."><plain>However, depending on the subtype, patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> still exhibit substantially different survival rates </plain></SENT>
<SENT sid="4" pm="."><plain>In <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e>, a mature B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, the addition of rituximab to conventional chemotherapy regimens has increased response rates, but not survival </plain></SENT>
<SENT sid="5" pm="."><plain>Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, the most aggressive BCL, is characterized by a high proliferative index and requires more intensive chemotherapy regimens than <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Hence, there is a need for more effective therapies for <z:hpo ids='HP_0000001'>all</z:hpo> three diseases </plain></SENT>
<SENT sid="7" pm="."><plain>Increased understanding of the molecular features of aggressive BCL has led to the development of a range of novel therapies, many of which target the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> in a tailored manner and are summarized in this paper </plain></SENT>
</text></document>